Biodesix Inc. (BDSX): Price and Financial Metrics
BDSX Price/Volume Stats
| Current price | $1.25 | 52-week high | $2.21 |
| Prev. close | $1.25 | 52-week low | $1.03 |
| Day low | $1.21 | Volume | 47,600 |
| Day high | $1.25 | Avg. volume | 151,995 |
| 50-day MA | $1.46 | Dividend yield | N/A |
| 200-day MA | $1.54 | Market Cap | 121.18M |
BDSX Stock Price Chart Interactive Chart >
Biodesix Inc. (BDSX) Company Bio
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.
Latest BDSX News From Around the Web
Below are the latest news stories about BIODESIX INC that investors may wish to consider to help them evaluate BDSX as an investment opportunity.
Zacks Industry Outlook Highlights Medpace, Doximity and BiodesixMedpace, Doximity and Biodesix have been highlighted in this Industry Outlook article. |
3 Medical Services Stocks to Buy as Industry Trends ImproveThe Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, DOCS and BDSX are set to gain the most. However, staffing shortages may disrupt the growth trend. |
Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw MethodBOULDER, Colo., November 14, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+™ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient’s upper arm. |
Biodesix to Participate in Two Upcoming Investor Conferences in NovemberBOULDER, Colo., November 09, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: |
Biodesix Announces Third Quarter 2023 Results and HighlightsBOULDER, Colo., November 07, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update. |
BDSX Price Returns
| 1-mo | -7.41% |
| 3-mo | -34.21% |
| 6-mo | -21.88% |
| 1-year | -24.70% |
| 3-year | -92.97% |
| 5-year | N/A |
| YTD | -32.07% |
| 2023 | -20.00% |
| 2022 | -56.52% |
| 2021 | -73.76% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...